secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001701478-25-000051
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q3 net loss widens to $2.8M; cash $1.4M; first patient dosed in ATR-04 Ph1/2 trial
--------------------------------------------------------------------------------

- Net loss of $2.8M for Q3 2025, compared to $1.0M in Q3 2024.
- Cash and equivalents $1.4M as of Sept 30, 2025; raised $2.8M gross via equity line from Alumni Capital.
- Dosed first patient in Phase 1/2 trial for ATR-04 targeting EGFRi-associated rash; FDA Fast Track granted.
- Presented positive preclinical data for ATR-01 (ichthyosis vulgaris) at BIO-Europe.
- R&D expenses $1.2M (up from $1.0M), G&A $1.6M (down from $1.9M) YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/0001701478-25-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/aztr-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001701478-25-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer